EGFR and leukemia: The compounds were screened against a panel of EGFR(+) (MCF-7/topo multidrug resistant breast adenocarcinoma) and EGFR(−) (518A2 melanoma, HL-60 leukemia, and KB-V1/Vbl cervix cancer) cancer cell lines.